

---

## Press Release

4 April 2019

### Immunicum AB (publ) Publishes the Annual Report for 2018

Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2018 is now available on the company's website, [www.immunicum.com](http://www.immunicum.com).

The Annual Report will be sent by regular mail to shareholders and other interested parties upon special request. For further information, please contact the company by telephone +46 8 732 8400 or e-mail, [info@immunicum.com](mailto:info@immunicum.com).

*This information is information that Immunicum is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 8:30 CEST on 4 April 2019.*

#### FOR MORE INFORMATION, PLEASE CONTACT:

Carlos de Sousa, CEO, Immunicum  
Telephone: +46 8 732 8400  
E-mail: [info@immunicum.com](mailto:info@immunicum.com)

Michaela Gertz, CFO, Immunicum  
Telephone: +46 70 926 17 75  
E-mail: [ir@immunicum.com](mailto:ir@immunicum.com)

#### MEDIA RELATIONS

Gretchen Schweitzer and Joanne Tudorica  
Trophic Communications  
Telephone: +49 172 861 8540  
E-mail: [ir@immunicum.com](mailto:ir@immunicum.com)

#### ABOUT IMMUNICUM AB (PUBL)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. [www.immunicum.com](http://www.immunicum.com)